Advertisement
Home »

High-Dose Simvastatin Does Not Slow Disability Progression in SPMS

Nov 11, 2024

REFERENCES & ADDITIONAL READING

  1. Chataway J, et al. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2 trial): a multicentre, randomised, placebo-controlled, double-blind phase 3 clinical trial. Abstract O134, ECTRIMS 2024, 17–20 October 2024, Copenhagen, Denmark.
  2. Chataway J, et al. Lancet. 2014;383(9936):2213-21.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement